Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03964090
Title Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

eye lymphoma

central nervous system lymphoma

Therapies

Cytarabine + Dexamethasone + Etoposide + Isavuconazole + Pegylated liposomal-doxorubicin + Rituximab + Temozolomide

Cytarabine + Dexamethasone + Etoposide + Ibrutinib + Isavuconazole + Pegylated liposomal-doxorubicin + Rituximab + Temozolomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.